The combination treatment of thymosin alpha-1 and lamivudine did not have an obvious benefit of virological and biochemical response as compared to the lamivudine monotherapy during the
combination period. In
addition, after the
cessation of thymosin alpha-1 treatment, the
combination therapy did not prevent the occurrence of viral and biochemical breakthroughs.